THURSDAY, Nov. 12 (HealthDay News) -- Early management of cediranib-induced hypertension is effective in patients with advanced cancers, according to a study published online Nov. 9 in the Journal of Clinical Oncology.
Marlies H.G. Langenberg, of University Medical Center Utrecht in the Netherlands, and colleagues randomly assigned 126 patients with advanced solid tumors to one of two doses of cediranib (30 or 45 mg per day) with or without antihypertensive prophylaxis. Patients who developed hypertension were managed with a standardized, predefined hypertension management protocol.
The researchers found that the drug was well tolerated and all four groups were able to achieve high-dose intensities in the first 12 weeks. All groups developed increased blood pressure that was successfully managed. No treatment strategy was clearly superior in reducing withdrawals from cediranib treatment. Only one patient receiving prophylaxis developed severe hypertension compared with 18 not receiving prophylaxis. Anti-tumor activity was observed with no apparent effect of cediranib dose or antihypertensive prophylaxis, with nine partial responses and 38 patients with stable disease at eight weeks or greater.
"The hypertension management protocol appears to be effective in managing cediranib-induced hypertension," Langenberg and colleagues conclude. "Rigorous monitoring of blood pressure during the first weeks of cediranib treatment and early intervention with antihypertensive therapy is likely to be helpful in optimizing the management of hypertension in patients taking cediranib."
The study, including medical writing by Mudskipper Bioscience, was supported by AstraZeneca. Several authors are employees of AstraZeneca.
Abstract
Full Text (subscription or payment may be required)
